Oct 30, 2024 / 01:00PM GMT
Kim Kelderman - Bio-Techne Corp - n President and Chief Executive Officer
From my end markets, combined with excellent execution by the biotech team led to 4% year-over-year organic revenue growth. Our growth pillars, including our molecular diagnostics for spatial biology platforms as well as our proteomic analysis franchise continue to outperform in constrained end markets.
It's also encouraging to see early indications of improvement in our biotech end markets, which is validated by the strength we experienced nerve cell and gene therapy business during this last quarter, I'll give additional details about the momentum in our growth pillars later in the call.
But first, I want to applaud the Bio-Techne team for delivering this top line performance for the continued focus on profitability. Jim will discuss this in more detail, but the cost containment and productivity initiatives we have put in place in recent quarters, position the company to being maintained its peer leading operating margin profile.
These efficiencies will also allow for continued strategic investments
Q1 2025 Bio-Techne Corp Earnings Call Transcript
Oct 30, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers